Balancing the cyclooxygenase portfolio

Armstrong, Paul W.
May 2006
CMAJ: Canadian Medical Association Journal;5/23/2006, Vol. 174 Issue 11, p1581
Academic Journal
Presents an opinion on issues associated with the introduction and withdrawal from general use of rofecoxib (Vioxx), a selective cyclooxygenase (COX)-2 inhibitor. Overview its mechanism of action; Risk associated with rofecoxib in elderly patients; Recommendation given by an expert advisory panel convened by Health Canada on the safety of COX-2 selective nonsteroidal anti-inflammatory drugs.


Related Articles

  • Progress in COX-2 Inhibitors: A Journey So Far. Chakraborti, Asit K.; Garg, Sanjeev K.; Kumar, Raj; Motiwala, Hashim F.; Jadhavar, Pradeep S. // Current Medicinal Chemistry;May2010, Vol. 17 Issue 15, p1563 

    The non-steroidal anti-inflammatory drugs (NSAIDs) are diverse group of compounds used for the treatment of inflammation, since the introduction of acetylsalicylic acid in 1899. Traditional (first generation) NSAIDs exert anti-inflammatory, analgesic, and antipyretic effects through the blockade...

  • NSAID Use in Individuals alt Risk of Renal Adverse Events. Roughead, Elizabeth E.; Ramsay, Emmae; Pratt, Nicole; Gilbert, Andrew L. // Drug Safety;2008, Vol. 31 Issue 11, p997 

    Background: Cyclo-oxygenase (COX)-2 inhibitors were introduced to world markets with claims of improved gastrointestinal safety compared with traditional NSAIDs. Randomized clinical trials had demonstrated fewer adverse gastrointestinal events with COX-2 inhibitors, but no difference with other...

  • Adverse Reaction Research.  // Reactions Weekly;12/6/2008, Issue 1231, p3 

    A conference paper about COX-2 inhibitors in subjects for whom blood pressure (BP) data were available is presented. It states that compared with placebo, the risk of developing new hypertension was increased with COX-2 inhibitors and this was driven largely by the increased risk associated with...

  • Effect of Rofecoxib on Pain Caused by Osteoid Osteoma. Carpintero-Benitez, Pedro; Aguirre, Maria Angeles; Serrano, Jose Antonio; Lluch, Mercedes // Orthopedics;Nov2004, Vol. 27 Issue 11, p1188 

    In a prospective study, nine patients with osteoid osteoma were treated with a selective cyclooxygenase-2 inhibitor (rofecoxib). Patient pain perception with no treatment, with conventional nonsteroidal anti-inflammatory drug (NSAID) treatment, and with rofecoxib therapy was compared using a...

  • Is rofecoxib safer than naproxen? Adelman, Alan // Journal of Family Practice;Mar2001, Vol. 50 Issue 3, p204 

    The article examines whether taking rofecoxib will lead to lesser gastrointestinal events than naproxen, a nonselective nonsteroidal anti-inflammatory drugs (NSAID). There are documents proving that older nonselective NSAID lead to adverse gastrointestinal effects. The events are caused by drug...

  • In Search of Safer NSAIDs: Which Cause the Least Risk of Upper GI Bleeding? Scherger, Joseph E. // Internal Medicine Alert;8/15/2010, Vol. 32 Issue 15, p115 

    A systematic review of 9 studies showed that the COX-2 inhibitor celecoxib and ibufrofen cause less upper GI bleeding than other NSAIDs. Diclofenac meloxicam, ketoprofen, indomethacin, and naproxen have intermediate risk. Piroxicam and ketorolac have the highest risk. In general, drugs that have...

  • Celecoxib No Safer Than Naproxen for Peptic Ulcer. Shaughnessy, Allen F. // American Family Physician;4/15/2006, Vol. 73 Issue 8, p1446 

    Discusses research on the efficacy of celecoxib versus lansoprazole and naproxen in preventing gastrointestinal ulcer complications. Reference to a study by K. C. Lai et al, published in the November 2005 issue of the "American Journal of Medicine"; Background on the study subjects; Details of...

  • Celecoxib Is as Effective as Diclofenac plus Omeprazole at Reducing Ulcer Bleeding. Chan, F. K;; Hung, L. C.; Suen, B. Y. // Annals of Internal Medicine;9/7/2004, Vol. 141 Issue 5, p375 

    This article presents information on effectiveness of various drugs used to treat ulcer bleeding. Current guidelines recommend that patients who are at risk for ulcer disease and require treatment for arthritis should receive either a cyclooxygenase-2 (COX-2) drug or a nonselective nonsteroidal...

  • COX-2s confer QOL benefit in clinical practice in Latin America. Everitt, Laura // PharmacoEconomics & Outcomes News;7/31/2004, Issue 458, p3 

    Discusses research being done on the effectiveness of cyclo-oxygenase-2 (COX-2) inhibitors etoricoxib and rofecoxib in treating patients with chronic low back pain or osteoarthritis in Latin American countries, presented at the Annual European Congress of Rheumatology in Berlin, Germany in June...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics